In­tra-Cel­lu­lar takes an­oth­er beat­ing af­ter the FDA rais­es a red flag on schiz­o­phre­nia drug safe­ty

In­tra-Cel­lu­lar Ther­a­peu­tics is dig­ging in deep to de­fend the trou­bling late-stage da­ta its re­searchers gath­ered on a lead drug for schiz­o­phre­nia. But now the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER